From: Primary localized retroperitoneal sarcomas: report from Slovenian sarcoma referral center
Characteristic | All patients, n = 89 | First period, n = 41 | Second period, n = 48 | p |
---|---|---|---|---|
Gender | 0.833 | |||
Male | 47 (52.8%) | 21 (51.2%) | 26 (54.2%) | |
Female | 42 (47.2%) | 20 (48.8%) | 22 (45.8%) | |
Age, median (years) | 62 (range 24–84) | 64 (range 31–82) | 62 (range 24–84) | 0.922 |
ASA score | 0.108 | |||
1 | 17 (19.1%) | 11 (26.8%) | 6 (12.5%) | |
2 | 43 (48.3%) | 17 (41.5%) | 26 (54.2%) | |
3 | 22 (24.7%) | 9 (22.0%) | 13 (27.1%) | |
4 | 4 (4.5%) | 1 (2.4%) | 3 (6.3%) | |
Unknown | 3 (3.4%) | 3 (7.3%) | 0 | |
Histologic subtype | 0.424 | |||
Dedifferentiated liposarcoma | 34 (38.2%) | 14 (34.1%) | 20 (41.7%) | |
Well-differentiated liposarcoma | 19 (21.3%) | 12 (29.3%) | 7 (14.6%) | |
Leiomyosarcoma | 14 (15.7%) | 7 (17.1%) | 7 (14.6%) | |
Solitary fibrous tumor | 8 (9.0%) | 3 (7.3%) | 5 (10.4%) | |
Malignant peripheral nerve sheath tumor | 2 (2.2%) | 0 | 2 (4.2%) | |
Other | 12 (13.5%) | 5 (12.2%) | 7 (14.6%) | |
FNCLCC Grade | 0.054 | |||
I | 31 (34.8%) | 21 (51.2%) | 10 (20.8%) | |
II | 16 (18.0%) | 5 (12.2%) | 11 (22.9%) | |
III | 30 (33.7%) | 13 (31.7%) | 17 (35.4%) | |
Unknown | 12 (13.5%) | 2 (4.9%) | 10 (20.8%) | |
Median tumor size (cm) | 21 (range 3–80) | 24 (range 7–80) | 19.5 (range 3–58) | 0.403 |
Radiotherapy | ||||
Neoadjuvant | 4 (4.5%) | 0 | 4 (8.3%) | 0.059 |
Adjuvant | 7 (7.9%) | 5 (12.2%) | 2 (4.2%) | 0.241 |
Chemotherapy | ||||
Neoadjuvant | 2 (2.2%) | 1 (2.4%) | 1 (2.1%) | 1.0 |
Adjuvant | 2 (2.2%) | 2 (4.9%) | 0 | 0.209 |
Surgical resection margin | 0.044 | |||
R0 | 68 (76.4%) | 27 (65.9%) | 41 (85.4%) | |
R1 | 21 (23.6%) | 14 (34.1%) | 7 (14.6%) | |
R2 | 0 | 0 | 0 | |
Median time to treatment (days) | 27.0 (range 0–181) | 16.0 (range 0–65) | 35.0 (range 4–181) | < 0.001 |
Median weight of the specimen (g) | 2259 (range 12–32,600) | 3450 (range 86–32,600) | 2006 (range 12–13,000) | 0.087 |
Stage (AJCC 8th edition) | 0.166 | |||
1A | 1 (1.1%) | 0 | 1 (2.1%) | |
1B | 42 (47.2%) | 23 (56.1%) | 19 (39.6%) | |
3A | 7 (7.9%) | 1 (2.4%) | 6 (12.5%) | |
3B | 39 (43.8%) | 17 (41.5%) | 22 (45.8%) | |
Median surgery duration (hours) | 7.3 (range 1.3–19.0) | 7.5 (range 2–14.5) | 7.0 (range 1.3–19) | 0.669 |
Median blood loss (l) | 1.0 (range minimal–32) | 0.8 (range minimal–32) | 1.4 (range minimal–30) | 0.853 |
Resection type | 0.266 | |||
Tumorectomy | 2 (2.2%) | 0 | 2 (2.2%) | |
Tumor removed with at least one organ, but not compartmental resection | 45 (50.6%) | 19 (21.3%) | 26 (29.2%) | |
Compartmental resection | 42 (47.2%) | 22 (24.7%) | 20 (22.5%) | |
Complication rate | 0.214 | |||
Clavien-Dindo 3a | 7 (7.9%) | 4 (9.8%) | 3 (6.3%) | |
Clavien-Dindo 3b | 9 (10.1%) | 5 (12.2%) | 4 (8.3%) | |
Clavien-Dindo 4a | 3 (3.4%) | 1 (2.4%) | 2 (4.2%) | |
Clavien-Dindo 4b | 3 (3.4%) | 0 | 3 (6.3%) | |
Clavien-Dindo 5 (90 days) | 5 (5.6%) | 0 | 5 (10.4%) | |
Median hospital stay after surgery (days) | 22.0 (range 2–102) | 23.0 (range 10–77) | 21.0 (range 2–102) | 0.952 |
Median ICU stay (days) | 8.0 (range 0–55) | 9.0 (range 4–22) | 7.5 (range 0–55) | 0.939 |